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Abstract: Background & Objective: Viral respiratory infections (VRI) have been commonly associated with exacerbation of 
wheezing in asthmatic children. Mycoplasma pneumoniae (MP) causes many respiratory syndromes that clinically mimic VRI. 
Due to the nature of the organism, cultures are of no practical value and the diagnosis is usually made by serology. Only a few 
studies have associated mycoplasma infections with acute exacerbations of wheezing in the asthmatic patient. This study was 
an attempt to assess the incidence of recent mycoplasma infections in patients with status asthmaticus and to review their 
laboratory, clinical and radiological findings. 
Methods: Retrospective review of all patients admitted to PICU over 12 month period with status asthmaticus. Recent 
mycoplasma infection was determined utilizing the Immunocard Mycoplasma Enzyme Immunoassay (EIA) for detection of 
MP IgM antibodies (Meredian Diagnostics, Inc., Cincinnati, OH) 
Results: The records of 44 patients were reviewed. 9 were excluded because MP tests were never obtained during 
hospitalization. 15/35 (42%) were MP Positive. There were no statistically significant differences (P>0.05) in length of 
hospitalization (LOH), ICU days, duration of continuous albuterol aerosol hours (cont. Nebs hrs.), days on O2 (02 days) or 
WBC between the two groups, however patients who were mycoplasma positive were treated with a macrolide antibiotic in 
addition to their standard asthma therapy. Patients with evidence of recent MP infection were more likely to have one or more 
infiltrates on their CXR (13/15 vs 7/20; P= 0.002). 
Conclusion: Our study suggests that recent MP infections play a significant role in exacerbations of asthma and occurrence of 
status asthmaticus in children. The presence of infiltrates on CXR in status asthmaticus warrants tests for MP. 
Keywords: Mycoplasma pneumoniae, asthma, status asthmaticus, chest X-ray infiltrates. 
INTRODUCTION 
  Status asthmaticus is among the leading causes of pediatric 
admissions to the hospital. Viral respiratory infections have 
been commonly associated with exacerbations of asthma in 
children [1].
 Only a few studies have associated mycoplasma 
infections with acute exacerbations of wheezing in the 
asthmatic patient [2-5]. In addition to being the most common 
cause of community acquired atypical pneumonia in children, 
Mycoplasma pneumoniae (M.P.) causes other respiratory 
syndromes such as bronchitis, bronchiolitis, pharyngitis and 
croup [6,7]. Many of these syndromes mimic viral respiratory 
infections in children. Due to the nature of the organism and its 
very slow growth rate, cultures have been of no practical 
clinical value and the diagnosis is usually made by serological 
methods [8]. 
  It has been our belief, as well as others, that recent 
mycoplasma infections play a much greater role in the 
pathophysiology of asthma and the precipitation of status 
asthmaticus than is readily recognized. We also suspected that 
infections with mycoplasma were often overlooked and not 
treated, and often times the infection was termed a “viral 
infection.” This study was an attempt to assess the incidence of 
recent mycoplasma infections in patients with status asth-
maticus that were admitted to our Pediatric Intensive Care 
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Unit and to review their laboratory, clinical, and radiological 
findings. 
METHODS 
  The medical records of all patients less than twenty years 
old with the diagnosis of status asthmaticus between September 
1997 and October 1998 were obtained. Status asthmaticus was 
defined as failure to respond to the usual appropriate initial 
emergency room treatment that included at least three albuterol 
aerosols, and necessitating PICU admission. Demographic, 
clinical and laboratory data were reviewed including age, sex, 
duration of asthma, hospital length of stay, ICU days, duration 
of oxygen treatment, duration of continuous albuterol aerosol 
treatments, mycoplasma IgM, initial radiological findings on 
chest x-ray and WBC count. Two groups of patients were 
identified: MP positive and MP negative patients. Comparison 
among variables between the two groups were then analyzed 
statistically by Chi square and Students’t-test. All patients 
suspected of having a respiratory tract infection in association 
with their asthma exacerbation were tested for Mycoplasma 
pneumoniae utilizing the Mycoplasma IgM rapid test on 
admission and the results were available within 2-4 hours. 
Patients that tested positive were started on a macrolide 
antibiotic in addition to the standard asthma treatment. All 
patients received systemic steroids as part of their therapy. 
Patients in whom the Mycoplasma IgM test was not obtained 
were excluded from the study. Chest x-rays were reviewed by a 
radiologist blinded to the results of the Mycoplasma IgM test, 36    The Open Respiratory Medicine Journal, 2008, Volume 2  Hanhan et al. 
 
and were considered positive if they demonstrated the presence 
of one or more infiltrates. 
 
Fig. (1). Chest X-ray of a patient in status asthmaticus who is 
Mycoplasma pneumoniae positive demonstrating bilateral basilar 
infiltrates. 
  Mycoplasma IgM rapid tests: The Immunocard Myco-
plasma Enzyme Immunoassay (EIA) (Meredian Diagnostics, 
Inc., Cincinnati, Ohio) is a qualitative procedure for the 
detection of IgM to mycoplasma pneumoniae. This methodo-
logy provides a simple to use, self-contained assay. No 
calculations are required and the visual color change makes 
interpretation of the results objective and simple. The test cards 
are individual foil pouches containing immobilized detergent 
extracted Mycoplasma pneumoniae antigens and human IgM. 
Included also are positive/negative controls, enzyme conjugate, 
wash buffer, and substrate reagents. The manufacturer’s 
directions were followed to perform the test in our laboratory. 
Performance characteristics of the Immunocard mycoplasma 
tests as published by the manufacturer showed a relative 
sensitivity of 88% (± 6%), relative specificity of 90% (± 3%), 
and agreement of 90% (± 3%) when compared with a 
microwell EIA. Discrepant results were resolved by 
Immunofluorescent Assays (IFA), latex and complement 
fixation testing (CFT). 
RESULTS 
  There were 44 patients with a diagnosis of status 
asthmaticus admitted to the PICU during the study period. 9 
patients were excluded because the mycoplasma IgM test was 
never obtained during the hospital period. Among the 
remaining 35 patients, 15 (42%) were mycoplasma IgM 
positive. Age range of the mycoplasma positive patients was 2-
19 years (mean 9.4 years) and there were 8 males and 7 
females. 20 patients (58%) were mycoplasma IgM negative, 14 
males and 6 females with an age range of 1.5 to 19 years (mean 
of 7.5). There were no statistically significant differences (P 
greater than 0.05) between the two groups in terms of length of 
hospitalization (LOH), ICU days, duration of continuous 
albuterol aerosols (Cont. Nebs Hrs.), days on oxygen (O2 days), 
or white blood cell count (Table 1). Patients who were 
mycoplasma positive were treated with a macrolide antibiotic 
in addition to their standard asthma therapy which included 
continuous albuterol nebulization at 0.3 mg/kg per hour, 
atrovent aerosols and systemic steroids. 
  13 (86%) of the 15 patients with positive mycoplasma IgM 
tests had a positive chest x-ray (infiltrates) on presentation vs 7 
(35%) of the 20 patients with negative mycoplasma IgM titers 
(P value =0.002). One of our patients had multiple admissions 
during the study period, was initially mycoplasma IgM 
negative on December 27, 1997 and January 25, 1998 and then 
became positive on one admission on February 18, 1998 and 
then negative subsequently on admission in April 1998. Her 
chest X-ray showed a left lower lobe infiltrate in February 
1998 and hyperinflation with no infiltrates on the April 1998 
admission. 
DISCUSSION 
  Acute exacerbation of wheezing in the asthmatic patient in 
association with respiratory tract infections has been well 
documented. Several studies have linked viral upper and lower 
respiratory infections as common precipitants of acute asthma 
exacerbations. Our study revealed an incidence of 42% of 
recent Mycoplasma pneumoniae infections among pediatric 
asthmatic patients admitted with acute exacerbation of their 
asthma and status asthmaticus. Recent infection was suggested 
by the presence of positive qualitative mycoplasma IgM 
against Mycoplasma pneumoniae. 
  Only a few studies have addressed the incidence of 
Mycoplasma pneumoniae infections in asthmatic patients. In a 
series of 84 children with asthma, Berkovich et al. [3] in 1970 
demonstrated a 32.1% incidence of viral or Mycoplasma 
pneumoniae infections during exacerbations of their disease. In 
their study significant changes in antibodies to Mycoplasma 
pneumoniae were found in 7 of the patients. (3 had evidence of 
Mycoplasma pneumoniae infection alone while 4 had 
Mycoplasma pneumoniae combined with a virus.) Gil et al. [9] 
Table 1.  Characteristic of Patients with Status Asthmaticus 
 
  Pts  Sex  *Mean Age (Yrs)  LOH (Days)  ICU (Days)  O2 Days  Cont Nebs (Hrs)  WBC  ** + CXR 
MP + 15  8  M  9.4  5.2  2.75  3.5  27.7  15.2  13 
MP - 20  14  M  7.5  4.65  2.65  3.35  29  13.6  7 
P- value NS  NS  NS  NS  NS  NS  NS  NS  0.002 
* Age Range 2-19 years. 
M = Male. 
** Presence of one or more infiltrates. 
LOH = Length of hospitalization. 
ICU = Length of ICU stay. 
O2 days = Duration of requirement for supplemental oxygen 
Cont Nebs = Duration of requirement for continuous nebulized albuterol. 
+ CXR = Chest X-ray abnormal. Association of Mycoplasma Pneumoniae Infections with Status Asthmaticus  The Open Respiratory Medicine Journal, 2008, Volume 2    37 
 
in a study of 77 patients with asthma and 88 persons without 
asthma (controls) demonstrated that Mycoplasma pneumoniae 
was isolated from 24.7% of asthmatic patients compared to 
5.7% of the control group, demonstrating a significantly higher 
colonization rate in the asthmatic patient. Yano et al. [10] 
demonstrated in a case report the onset of bronchial asthma 
symptoms following a recent mycoplasma infection. They also 
found the presence of IgE antibodies specific to Mycoplasma 
pneumoniae in that patient. Tipirneni et al. [5] detected IgE 
antibodies to Mycoplasma pneumoniae in 5 of 152 patients 
with asthma and other atopic diseases. Seggev et al. [2], in a 
study of 95 adult patients (mean age of 45.7 years) hospitalized 
due to acute asthma, demonstrated that 21% of these patients 
had evidence of a recent Mycoplasma pneumoniae infection. 
Other studies [11] have also suggested a role for Chlamydia 
pneumoniae infections in association with both acute and 
chronic wheezing. 
  In contrast to these studies, others have not found evidence 
of Mycoplasma pneumoniae infections among adults and 
children with acute asthma. Minor et al. [12] in their study 
found an increased incidence of viral URIs during 
exacerbations of asthma but no evidence of Mycoplasma 
pneumoniae. Berman et al. [13] in a study based exclusively on 
cultures of trans-tracheal aspirates, found no evidence of any 
infection associated with exacerbations of asthma. 
  Our study does demonstrate a high incidence of recent 
mycoplasma infections as demonstrated by a positive 
mycoplasma IgM test. This along with other studies suggests a 
much greater role for mycoplasma infections in the acute 
exacerbation of asthma. We were unaware of any epidemic of 
Mycoplasma pneumoniae in our area during the time of the 
study period. 
  Direct detection of Mycoplasma pneumoniae infections by 
culture is currently difficult because of the slow growth rate of 
the organism and fastidious growth requirements. For this 
reason, serology is often the best laboratory method available. 
Various formats are available to test patients’ sera to 
Mycoplasma pneumoniae. Complement fixation detects IgM 
and IgG, and although it has been used extensively in the past, 
recent evidence suggests that it lacks specificity. Similarly, 
cold agglutinin serology is both insensitive and non-specific in 
children younger than 12 years of age, and many experts have 
recommended against requesting cold agglutinins for pediatric 
age groups [7]. On the other hand, enzyme-linked 
immunosorbent assays (ELISA) are sensitive and adaptable and 
most of the serologic tests used now are based on the ELISA 
format. Although obtaining paired sera for the detection of IgM 
and IgG in the acute and convalescence phases of an infection 
would usually establish the diagnosis during convalescence and 
would be useful to assess prevalence of past infections, most 
clinicians would like to confirm the diagnosis early during the 
acute infection. Therefore serological determination of current 
mycoplasma infection by a single, acute-phase serum sample 
often is the only diagnostic test used in routine clinical care. 
Some disadvantages to this method, however, are that even 
though specific IgM antibodies to Mycoplasma pneumoniae are 
usually detected in patients with a recent primary infection, 
they may be found in patients with reactivated or secondary 
infections and are sometimes found in patients with no other 
detectable evidence of recent infection (unapparent infections.) 
Utilizing IgM serology, however, will help detect most recent 
and some past Mycoplasma pneumoniae infections and 
therefore clinical correlation in interpreting the results is 
important. Similarly, Mycoplasma pneumoniae can be 
recovered by culture or PCR from the respiratory tract up to 
several weeks after an acute infection often times despite 
antibiotic use, making the interpretation of those results 
difficult as well (colonization versus acute or chronic 
infection). Even after accounting for the limitation of the 
Immunocard Mycoplasma EIA test that we used in our study 
(sensitivity 88% - specificity 90%, and 90% agreement when 
compared with a microwell EIA), it is still apparent that 
mycoplasma infections are frequently seen in association with 
acute asthma exacerbations. Our study also found no 
significant differences in length of hospitalization, ICU stay, 
days on oxygen, continuous albuterol aerosol requirements, or 
WBC, between mycoplasma positive and mycoplasma negative 
patients. However, it should be noted that all of our patients 
who were found to be mycoplasma IgM positive were treated 
with a macrolide antibiotic in addition to their standard 
asthmatic treatment within six hours of admission to the 
hospital. Whether such antibiotic treatment had a beneficial and 
positive effect on the clinical progress of these patients is yet to 
be determined. 
  One significant and important finding of this study is the 
frequency of finding a positive Chest X-ray (infiltrates) in 
those asthmatics who were Mycoplasma IgM positive. All 
chest x-rays were reviewed by a radiologist blinded to the 
results of the Mycoplasma IgM test, and were considered 
positive if they showed one or more definite infiltrates. 
Although infiltrates or variable opacifications are not 
uncommon in asthmatic patients and may represent atelectasis 
from mucous plugging rather than infection, the difference 
between the two groups was very significant. (13 of the 15 
patients who were mycoplasma positive versus 7 of 20 patients 
who were Mycoplasma negative, P=0.002). This finding would 
suggest that the presence of one or more infiltrates in patients 
with status asthmaticus warrants testing for the presence of 
recent mycoplasma infection. The Mycoplasma EIA 
Immunocard test costs $227.00 for a kit of 28 tests including 
mandatory controls. 
  Our study has a number of limitations. It was a 
retrospective study, the diagnostic test does not differentiate 
with absolute certainty recent from remote or reactivated 
Mycoplasma infections, but neither does the PCR or the 
cultures. Other important infectious agents associated with 
status asthmaticus such as viruses, were not examined in our 
study. Nevertheless we found a high incidence of mycoplasma 
infections in our patients presenting with status asthmaticus. 
  In a recently published study, Kraft et al. [14] detected the 
presence of Mycoplasma pneumoniae by PCR in 
bronchoalveolar lavage and biopsy specimens in 10 of 18 
chronic stable asthmatics (55%) and in 1 of the 11 control 
subjects, suggesting the presence of Mycoplasma pneumoniae 
in the lower airways of chronic stable asthmatics with 
significantly greater frequency than in the control non-
asthmatic subjects. All of the patients, however, who had the 
organism detected by polymerase chain reaction (PCR) had 
negative cultures, EIAs and serology for Mycoplasma 
pneumoniae in this study. The authors in their discussion state 
that PCR positivity can be present for longer periods than 
culture or seropositivity. They hypothesize that these asthmatic 38    The Open Respiratory Medicine Journal, 2008, Volume 2  Hanhan et al. 
 
patients are chronically infected or colonized with Mycoplasma 
pneumoniae. 
  In a related study Martin et al. [15] extended their initial 
report to include a total of 55 chronic stable asthmatics and 11 
normal control subjects. In this study 25 of the 55 asthmatics 
had positive PCR results for Mycoplasma and 6 for Chlamydia, 
strongly suggesting that both Mycoplasma pneumoniae and 
Chlamydia are found in asthmatic airways. Furthermore they 
noted the presence of increased numbers of mast cells in the 
group with positive PCR results suggesting a potential 
interaction between chronic infection and allergen 
sensitization. Again as with the original study, all cultures and 
serology for Mycoplasma were negative in both asthmatics and 
control groups. 
  Despite our understanding of the histopathology of 
mycoplasma infections and its attachment to the ciliated 
respiratory epithelial cells, it remains unclear what mechanism 
this bacteria employs to cause injury and harm to the 
respiratory cells. It is also unclear whether it triggers an 
immune- mediated response that causes bronchospasm. 
Whether Mycoplasma pneumoniae plays a significant role in 
the pathogenesis of both acute and chronic asthma is yet to be 
determined. If in fact it does, then treatment of selected groups 
of asthmatics with anti-mycoplasma antibiotics might prove to 
be beneficial. 
CONCLUSION 
  Although the association of the respiratory infections with 
the exacerbation of asthma has been described in the literature, 
as we alluded in our discussion, only a few studies have shown 
an association of Mycoplasma pneumoniae infections with 
asthma and especially with status asthmaticus. Also an equal 
number of studies have failed to show any association of 
Mycoplasma  pneumoniae infections with exacerbation of 
asthma. 
  We think our study adds new information especially 
relevant to pediatric practice because we addressed status 
asthmaticus in children. Mycoplasma pneumoniae is an 
important organism associated with status asthmaticus and 
acute exacerbation of asthma in children and the presence of 
infiltrates on chest x-ray in status asthmaticus warrants testing 
for Mycoplasma pneumoniae. 
  Whether treating Mycoplasma pneumoniae positive patients 
with macrolide antibiotic is beneficial or not is something we 
are addressing in a subsequent study. 
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